10% INTRAVENOUS IMMUNOGLOBULIN GAMUNEX IN THE TREATMENT OF PRIMARY IMMUNODEFICIENCIES PATIENTS: OWN EXPERIENCE AND LITERATURE REVIEW

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Intravenous immunoglobulin G preparation (IVIG) is an effective and safe therapeutic modality in the primary immunodeficiencies (PID) management. We investigated effectiveness and safety of the 10% preparation of IVIG Gamunex in treatment of 26 patients with primary immunodeficiencies at ages 8 months 17 years. Percentage of nonsevere reactions to Gamunex infusions was similar as to other 5% IVIG preparations (2,9 vs 2,8%). Average time of infusion was reduced from 88 minutes for 5% IVIG to 67 minutes for Gamunex. Average trough IgG level after Gamunex infusions was sufficient (6,8 g/l) and resulted in the absence of significant infectious episodes in PID patients during the study period. Our study demonstrated good efficacy and safety profile of Gamunex.

Full Text

Restricted Access

About the authors

I N Smirnova

Federal Research and Cinical Center for Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Ministry of Health

T G Kosacheva

Federal Research and Cinical Center for Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Ministry of Health; Children's City Clinical Hospital No. 9, named after G.N. Speransky

O V Shvetz

Children's City Clinical Hospital No. 9, named after G.N. Speransky

S B Zimin

Children's City Clinical Hospital No. 9, named after G.N. Speransky

A Yur'evna Shcherbina

Federal Research and Cinical Center for Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Ministry of Health

Email: shcher26@hotmail.com

References

  1. Ochs H.D., Hitzig WюH. History of primary immunodeficiency diseases. Curr. Opin. Allergy Clin. Immunol. 2012, v. 12, р.577-587.
  2. Hinman J., Tullis J.L., Saravis C.A., Pennell R.B. Intravenous use of plasmin treated immunoglobulin G.I. Preliminary report on tolerance by immunologically deficient patients. Vbx. Sang. 1967, v. 13, р. 85-90.
  3. Maarschalk-Ellerbroek J., Hoepelman I.M., Ellerbroek P.M. Immunoglobulin treatment in primary antibody deficiency. Int. J. Antimicrob. Agents. 2011, v. 37, р. 396-404.
  4. Dickler H.B., Gelfand E.W Current perspectives on the use of intravenous immunoglobulin. Adv. Intern. Med. 1996, v. 41, р. 641-680.
  5. Navarro R.P., Ballow M., Fenrick B., Pezalla E.J. Considerations for optimal use of immunoglobulin. Am. J. Manage Care. 2012, v. 18, р. 67-78.
  6. Aukrust P., Froland S.S., Liabakk N.B. et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood. 1994, v. 84, р. 136-143.
  7. Eijkhout H.W., van der Meer J.W.M., Kallenberg C.G.M. et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. Ann. Intern. Med. 2001, v. 135, р. 165-174.
  8. Orange J.S., Grossman W.F., Navickis R.J., Wilkes M.M. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin. Immunol. 2010, v. 137, p. 21-30.
  9. Roifman C.M., Schroeder H., Berger M. et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int. Immunopharmacol. 2003, v. 3, р. 1325-1333.
  10. Ballow M., Berger M., Bonilla F.A. et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). Vox. Sang. 2003, v. 84, р. 202-210.
  11. Teschner W., Butterweck H.A., Auer W. et al. A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process. Vox. Sang. 2007, v. 92, р. 42-55.
  12. Lundblad J.L., Seng R. Inactivation of lipid-enveloped viruses in proteins with caprylate. Vox. Sang. 1991, v. 60, р. 75-81.
  13. Lebing W., Remington K.M., Schreiner C., Paul H.I. Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography. Vox. Sang. 2003, v. 84, р. 193-201.

Statistics

Views

Abstract: 142

Article Metrics

Metrics Loading ...

Dimensions

PlumX


Copyright © Pharmarus Print Media, 2014



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies